Cancer affects millions of people around the world — not only those diagnosed, but also the families, communities and care teams around them.
Season two of Rewriting Cancer explores the people and progress helping to change how cancer is detected, treated and understood — from earlier detection to new approaches to prevention, diagnosis and treatment.
This film explores how artificial intelligence is reshaping breast cancer screening, supporting radiologists in clinical practice today to help improve detection, bring greater consistency across populations and find cancers that may otherwise be difficult to see.
Breast Suite
AI-powered, end-to-end breast imaging screening and diagnostic workflow applications, seamlessly integrated into your IT
Enables more accurate diagnosis1,2 with the use of priors3 and automatic localization of regions of interest and degree of suspicion
Provides consistent, automated density classification with a patient-centric, accurate density assessment of 2D or 3D mammograms to support objective diagnostic decisions.
Identifies high risk of developing breast cancer in 1-2 years, based only on a mammogram calibration, with up to x2.4 more accurate than traditional risk models6,7
Automated ultrasound image analysis and lesion detection and characterization according to ACR BI-RADS guidelines.
Building Patient Trust in AI-Powered Breast Screening
Building patient trust in AI-powered breast screening starts with clinician confidence. As radiologists increasingly integrate AI into mammography workflows, understanding how to confidently and clearly communicate AI’s role becomes essential for both patient acceptance and program success. While AI-powered mammography has been shown to increase breast cancer detection rates, many clinicians face questions from theirpatients.
Learn moreReal World Impact
Improve cancer detection rates with second reviewer workflow
DM (2D)
DBT (3D)
Breast Suite
Clinical impact at scale
Delivered with superior accuracy, driven by our algorithm trained on vast clinical data 6, 7
Explore Clinical Evidence21%
increased cancer detection rate (CDR)1
23%
more cancers detected in women with dense breasts1
20%
more cancers detected in Black/African American women1
Specialist level care
achieved by a group of general radiologists¹¹
Real voices.
Real impact.
Dr. Janet Storella
Medical Director, Women’s Imaging, Maryland RadNet East
“It's like having my trusted colleague sitting next to me, helping me work through the most difficult cases.”
Jason R. Sinner M.D.
Medical Director, RadNet/BRMG
“It has made me considerably more efficient due to decreased lag between loading patient studies, in particular as it relates to breast tomography where I can instantly review the current study along with multiple prior exams.”
Dr. Jacqueline Holt
Medical Director, Women’s Imaging, Delaware Imaging Network, RadNet
“Breast Suite applications help me read smarter and more efficiently. It allows me to sort and prioritize mammograms most likely to have cancer in them and draws my attention to what really matters in each image.”
Empowering breakthroughs in care through imaging
Our Mission
Imaging is the core of the diagnosis process, and we aim to empower breakthroughs in care by unlocking its value. To tackle clinical and operational challenges that arise in complex, high-volume care settings, we harness the power of AI for better outcomes.
Screening at scale
Discover how our AI-powered solutions are transforming healthcare by providing advanced imaging and data analytics to improve patient outcomes and operational efficiency.
Find out more
Learn more
Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth’s Novel AI-Powered Breast Cancer Detection Workflow
LOS ANGELES and SOMERVILLE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), the nation’s largest provider of outpatient diagnostic imaging services, and its wholly owned subsidiary, DeepHealth, a global leader in AI-powered health informatics, today announced results from the largest real-world analysis of AI-driven breast cancer screening ever conducted in the United States.1
DeepHealth Expands Breast Suite with New FDA-Cleared AI Capabilities
GE HealthCare expands mammography collaboration with RadNet’s DeepHealth subsidiary to extend global access to DeepHealth’s AI-powered breast cancer screening solutions
CHICAGO – April 16, 2026 – GE HealthCare (Nasdaq: GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools.